Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Hézode

Showing results (1-10 of 89) with videos related to

Pageof 9
Sort By:
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 5, 2013
Management of anaemia and other treatment complicationsChristophe Hézode
Liver International : Official Journal of the International Association for the Study of the Liver|January 5, 2016
Why I do not treat patients for mild diseaseChristophe Hézode
Liver International : Official Journal of the International Association for the Study of the Liver|January 4, 2012
Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practiceChristophe Hézode
Clinics and Research in Hepatology and Gastroenterology|January 18, 2012
Direct-acting antiviral (DAA) actions in treatment-naïve patientsChristophe Hézode
Liver International : Official Journal of the International Association for the Study of the Liver|February 11, 2018
Treatment of hepatitis C: Results in real lifeChristophe Hézode
Journal of Hepatology|September 28, 2015
Ideal oral combinations to eradicate HCV: The role of ribavirinChristophe Hézode, Jean-Pierre Bronowicki
La Revue Du Praticien|July 14, 2010
[Chronic hepatitis B: antiviral treatment guidelines]Christophe Hézode, Jean-Michel Pawlotsky
Journal of Hepatology|February 4, 2012
Antiviral strategies in hepatitis C virus infectionChristoph Sarrazin, Christophe Hézode, Stefan Zeuzem, et al.
Journal of Hepatology|December 11, 2012
Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikelyStéphane Chevaliez, Christophe Hézode, Stéphane Bahrami, et al.
Hepatology (Baltimore, Md.)|June 24, 2008
Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosisAurélie Piodi, Philippe Chouteau, Hervé Lerat, et al.
Pageof 9

Showing results (1-10 of 89) with videos related to

Sort By:
Pageof 9
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 5, 2013
Management of anaemia and other treatment complicationsChristophe Hézode
Liver International : Official Journal of the International Association for the Study of the Liver|January 5, 2016
Why I do not treat patients for mild diseaseChristophe Hézode
Liver International : Official Journal of the International Association for the Study of the Liver|January 4, 2012
Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practiceChristophe Hézode
Clinics and Research in Hepatology and Gastroenterology|January 18, 2012
Direct-acting antiviral (DAA) actions in treatment-naïve patientsChristophe Hézode
Liver International : Official Journal of the International Association for the Study of the Liver|February 11, 2018
Treatment of hepatitis C: Results in real lifeChristophe Hézode
Journal of Hepatology|September 28, 2015
Ideal oral combinations to eradicate HCV: The role of ribavirinChristophe Hézode, Jean-Pierre Bronowicki
La Revue Du Praticien|July 14, 2010
[Chronic hepatitis B: antiviral treatment guidelines]Christophe Hézode, Jean-Michel Pawlotsky
Journal of Hepatology|February 4, 2012
Antiviral strategies in hepatitis C virus infectionChristoph Sarrazin, Christophe Hézode, Stefan Zeuzem, et al.
Journal of Hepatology|December 11, 2012
Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikelyStéphane Chevaliez, Christophe Hézode, Stéphane Bahrami, et al.
Hepatology (Baltimore, Md.)|June 24, 2008
Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosisAurélie Piodi, Philippe Chouteau, Hervé Lerat, et al.
Pageof 9